Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study

Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study

The randomized FIRE‐4.5 (AIO KRK0116) trial compared first‐line therapy with FOLFOXIRI (folinic acid, fluorouracil, oxaliplatin, and irinotecan) plus either cetuximab or bevacizumab in B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) V600E‐mutant metastatic colorectal cancer (mCRC) patients. Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel, Thomas Mika, Roland Schroers, Swantje Held, Kathrin Heinrich, David Tougeron, Dominik P. Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Müller, Christof Burkart, Sebastian Stintzing, Volker Heinemann
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Molecular Oncology
Subjects:
bevacizumab
cetuximab
circulating tumor DNA
FOLFOXIRI
liquid biopsy
mutational load
Online Access:https://doi.org/10.1002/1878-0261.13778
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/1878-0261.13778

Similar Items